If excessive legacy scale is a barrier to focus, re-basing remains an option—shedding non-core assets and aligning investment
and capabilities around a related set of opportunities.
In the future, there will be no common model, no shared success template. As industry leaders learn to play by new rules,
they will need to experiment more radically—not just with choices about channel, breadth, and disease focus, but also with
choices involving geographic scope, product and service integration, and where to play in the value chain.
Jerry Cacciotti is managing director and Bill Shew is a principal of SDG's Life Science practice. he can be contacted at email@example.com